Immunome, Inc. (NASDAQ: IMNM) shares gained +24.49 during the trading session of Thursday. The strong performance of the firm has highlighted the positive reactions of the investors after the firm disclosed that it is successful in finding the antibodies that have the ability to counteract against the several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus experimentation.
The discovery of a new antibody has excited the stock of the firm as its share rocketed 113.46% at $47.43 at the time of writing. During the trading session of Thursday, it has recorded a trading volume of 6.46 million as compared to the average volume of 85.56K.
This discovery is part of the ongoing program of the firm to create a combination of antibodies. The firm is trying to create antibodies that can target both spike and non-spike protein that will become a cure for the novel coronavirus. The COVID-19 antibody analysis of IMNM shows that SARS-CoV-2 "super-responders" who get better from SARS-CoV-2 display a strong immune reaction to a wide range of viral targets, involving spike and non-spike proteins.
During the creation of a combination of antibodies, IMNM has discovered the antibody which has the ability to get attached to the non-intersecting areas of spike protein as well as those areas where the mutational variants lie. This is the greatest accomplishment of the firm during its history.
The analysis of IMNM disclosed that some of its antibodies counteract pseudoviruses containing the spike protein of the South African Variant (B.1.351). The latest Available literature proposes that this South African Variant lessens the efficacy of certain inoculations and antibody treatments. IMNM has earlier got the $13.3 million technology grant from JPEO-CBRND in cooperation with the Defense Health Agency, in order to assist the Immunome’s COVID program.